Optimizing biologic treatment in IBD: objective measures, but when, how and how often?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,General Medicine
Link
http://link.springer.com/content/pdf/10.1186/s12876-015-0408-x
Reference63 articles.
1. Peters CP, Eshuis EJ, Toxopeüs FM, Hellemons ME, Jansen JM, D'Haens GR, et al. Adalimumab for Crohn's disease: long-term sustained benefit in a population-based cohort of 438 patients. J Crohn Colitis. 2014;8:866–77.
2. Reinisch W, Wang Y, Oddens BJ, Link R. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther. 2012;35:568–76.
3. Jürgens M, Mahachie John JM, Cleynen I, Schnitzler F, Fidder H, van Moerkercke W, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011;9(5):421–7.e1.
4. Arias MT, Vande Casteele N, Vermeire S, de Buck van Overstraeten A, Billiet T, Baert F, et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13(3):531–8.
5. Monterubbianesi R, Aratari A, Armuzzi A, Daperno M, Biancone L, Cappello M, et al. Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). J Crohns Colitis. 2014;8:852–8.
Cited by 36 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Grifola frondosa polysaccharide's therapeutic potential in oxazolone-induced ulcerative colitis;Carbohydrate Polymers;2024-11
2. Bioinspired and bioderived nanomedicine for inflammatory bowel disease;WIREs Nanomedicine and Nanobiotechnology;2024-07
3. Clinical use of biologics for Crohn’s disease in adults: lessons learned from real-world studies;Expert Opinion on Biological Therapy;2024-02-23
4. Treatment of Inflammatory Bowel Disease with Biologics in Japan: A Single-Center, Retrospective Pharmacoeconomic Study;Biological and Pharmaceutical Bulletin;2024-01-20
5. Effectiveness of Partial Enteral Nutrition as Add-On to Biologics in Patients With Refractory and Difficult-to-Treat Crohn’s Disease: A Pilot Study;Crohn's & Colitis 360;2024-01-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3